Financial Growth and Transition at SOPHiA GENETICS
The Company finishes 2025 with impressive Q4 performance, foresees 20-22% revenue growth in 2026, and promotes Ross Muken to CEO.
Preliminary Fourth Quarter Financial Highlights
SOPHiA GENETICS, a leader in AI-driven precision medicine, has announced preliminary results for the fourth quarter of 2025. The company reported a revenue of at least $21 million, showing a year-over-year growth of about 20%. Additionally, it executed over 105,000 analyses on its SOPHiA DDM™ platform, marking a 16% increase compared to the previous year.
Full Year Financial Overview
In 2025, SOPHiA GENETICS achieved approximately $77 million in revenue, reflecting an 18% rise from the previous year. The company performed more than 391,000 analyses on its SOPHiA DDM™ platform, establishing a new record for the organization.
Guidance for 2026
Looking ahead, SOPHiA GENETICS is optimistic about its financial outlook for 2026. The company anticipates a revenue range between $92 million and $94 million, representing a year-over-year growth of 20% to 22%. However, adjustments are expected, leading to an EBITDA loss estimated between $29 million and $32 million.
Executive Transition Plan
As part of its strategic planning, SOPHiA GENETICS has announced the promotion of Ross Muken to Chief Executive Officer, effective July 1, 2026. Muken, who has served as President and has been instrumental in the company’s operations for five years, will take over from Jurgi Camblong, who will transition to the role of Executive Chairman.
Dr. Jurgi Camblong, the co-founder, has been pivotal in steering SOPHiA GENETICS towards its growth trajectory. In his new role as Executive Chairman, he will continue to focus on strategic initiatives, innovation, and the long-term direction of the company.
Board’s Perspective on Transition
According to Dr. Tomer Berkovitz, a Board Member, the executive changes indicate a well-thought-out succession plan, reflecting the commitment to ensuring the company’s foundation and future growth. He praised Dr. Camblong’s efforts in developing a pioneering application of AI in precision medicine.
Ross Muken's Journey at SOPHiA GENETICS
Ross Muken joined SOPHiA GENETICS as Chief Financial Officer in early 2021, just before the company’s initial public offering. His journey through various leadership roles, including Chief Operating Officer, has prepared him to lead the company into its next strategic phase. His extensive experience has been crucial in reestablishing the company's commercial viability and operational efficiency.
Looking Ahead
The company has indicated that it is set for continuous growth, attributing its success to its innovative Liquid Biopsy application, MSK-ACCESS, as well as promising opportunities in the U.S. market and a renewed focus on its BioPharma business. The leadership team is excited to build on the successes achieved in 2025, maintaining a solid performance outlook for 2026.
About SOPHiA GENETICS
SOPHiA GENETICS (NASDAQ: SOPH) is dedicated to leveraging AI to enhance access to precision medicine on a global scale, aiming to improve patient care for individuals with cancer and rare disorders. The company's flagship product, SOPHiA DDM™, offers a sophisticated platform that delivers actionable insights from complex genomic data. Through strategic partnerships and cutting-edge technology, SOPHiA GENETICS continues to expand its impact across healthcare institutions worldwide.
Frequently Asked Questions
What were the preliminary financial results for Q4 2025?
SOPHiA GENETICS reported a revenue of at least $21 million for Q4 2025, representing a year-over-year growth of about 20%.
What is the revenue guidance for 2026?
The company forecasts revenue between $92 million and $94 million for the full year 2026, with anticipated growth of 20-22%.
Who is the new CEO of SOPHiA GENETICS?
Ross Muken has been promoted to Chief Executive Officer, effective July 1, 2026, succeeding co-founder Jurgi Camblong.
What is SOPHiA GENETICS' core mission?
The mission of SOPHiA GENETICS is to democratize data-driven medicine using AI to provide world-class care to patients globally, particularly in cancer and rare disorders.
When will the complete financial results for 2025 be available?
The complete financial results for Q4 and the full year of 2025 are expected to be reported during the first earnings call of 2026, scheduled for March 3, 2026.
